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ABSTRACT
Introduction: Acute myeloid leukemia is a group of neoplasm of the bone marrow that
hasclinical similarity but has but a specific cellular morphology and genetics.AML includes
about 90-80% of adult acute leukemia and is the third leading cause of death due to cancer in
people aged 30-18 years old. So, this study aims to examine patients with AML in a clinical
laboratory manner who have been diagnosed over six years (2010-15) in Hematology-Oncology
section of Namazi hospital and admitted there.
Method: By using acute myeloid leukemia patients' records who had been hospitalized six years
(94-89) in Hematology-Oncology section of Namazi hospital, this study was performed
retrospectively.The necessary data included age, sex, diagnosing leukemia type, place of birth,
occupation, time of admission and discharge, duration of hospitalization, the patient's chief
complaint and other complaints, the duration of the preliminary symptoms prior to diagnosis,
history of smoking and exposure to radiation or chemicals, physical examination findings and
laboratory findings including blood chemistry and bone marrow, study of cerebrospinal fluid in
case it had been done, positive culture and information relating to the treatment of early
response, duration of remission, complications of induction of remission and the time of
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recurrence and death and the cause of death, all of which were recorded in a form that was
attached. The results of this study are indicated in an observational way. But, wherever it was
possible, comparison was done and this comparison was evaluated using Z test. P <0.05 is
significant.
Results: During this period, 244 patients were diagnosed and hospitalized that 141 of them
(58%) were male and 103 (42%) were female. Then, M1 with (20%), M2 (6/19%) and M3 with
18.3% are ordered. Finally M5 with 8%,and M7 and Hybrid each with 1.2% and M6 with 0.8%
are classified in the next ranks.Most patients were from the age group of 29-20 years. Regardless
of the type of leukemia and sex,the average age of our patients was 36/17 years (SD 16/11 ±
years). The worst prognosis of M3 was death initial response to chemotherapyin 52.5% and the
best prognosis of M2 was death as the initial response to treatment in 27.5%. The most common
cause of death in our patients was first bleeding with 38.5% and then infection with 27%.
Conclusion: Acute myeloid leukemia, unlike in other parts of the world,is still a lethal disease
with anominous sequel among our young population. Swollen lymph glands and organs are more
common in patients. A closer examination and laboratory examination, at least a complete blood
test in suspected patients could be life-saving.
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1. INTRODUCTION
The presence of genetic factors in A.N.L.L based on the observation of an increased risk of
A.N.L.L in patients is associated with congenital defectssuch as Down syndrome and Klinefelter.
The risk of leukemia in Down syndrome is ten times higher than the normal population [1-
2].Diseases associated with chromosomal instability and increased chromosome breakage
include Fanconi anemia, ataxia telangiectasia, Bloom syndrome and Vyskvt Aldrich [4-5], that
are coupled with the increased prevalence of A.N.L.L;and diseases like One Rklyng Hazvn and
congenital neurofibromatosis are associated with an increased prevalence of C.L.L in childhood
[3]. Environmental factors are also involved in the pathogenesis of AML [6]. There are only
three environmental factors that are well known as causes of AML including:getting too much
radiation, chronic exposure to benzene and Lkalyt [3]. Evidence on the association of leukemia
and radiation in Hiroshima and Nagasaki atomic bomb survivors has been seen. The time its
incidence was from 5 to 21 years after the explosion. Risk depends on age at the time of the
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explosion and the dose of radiation [2, 4]. The highest incidence was among those under 10-
year-old and 50-year-old [2]. Symptoms of acute leukemia in most patients are a period of less
than three months [5]. Signs and symptoms that show the onset of AML include pallor,
weakness, fatigue, palpitations and dyspnea on exertion which indicates anemia. However,
weakness and feeling of well-being cannot be linked to the severity of anemia. Bruising due to
trivial shot, palpitation, epistaxis, gingival bleeding and prolonged bleeding from skin lesions,
indicative of thrombocytopenia, are among the initial manifestations of the disease. Incidence of
bleeding from the stomach, intestines, genital tract, lungs or central nervous system, though low,
can be a part of the initial manifestations [3].
2. METHOD
By using acute myeloid leukemia patients' records who had been hospitalized six years (94-89)
in Hematology-Oncology section of Namazi hospital, this study was performed retrospectively.
According to the list Archive of Shahid Motahhari clinic, 352 people were hospitalized due to
AML during this period,244 of whom were aged 14 years or older and had been diagnosed for
the first time.The necessary data included age, sex, diagnosing leukemia type, place of birth,
occupation, time of admission and discharge, duration of hospitalization, the patient's chief
complaint and other complaints, the duration of the preliminary symptoms prior to diagnosis,
history of smoking and exposure to radiation or chemicals, physical examination findings and
laboratory findings including blood chemistry and bone marrow, study of cerebrospinal fluid in
case it had been done, positive culture and information relating to the treatment of early
response, duration of remission, complications of induction of remission and the time of
recurrence and death and the cause of death, all of which were recorded in a form that was
attached. Unfortunately, because of incomplete records available including not having
writtenpatients’ job or restricting the report to mentioning jobs in general, say writing only
“worker”, regardless of the place of work, the relationship between occupation and type of
leukemia rendered impossible.Moreover, the relationship between smoking and HDL in
prognosis and the risk of leukemia was not statistically significant,so they were excluded from
the study. The rest of the data were analyzed after extraction. The results of this study are
indicated in an observational way. But, wherever it was possible, comparison was done and this
comparison was evaluated using Z test. P <0.05 is significant.Concerning the median duration of
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remission and survival and the duration of initial symptoms of leukemiaprior tothe diagnosis
because data range was too broadand the standard deviation was larger than the average in these
three cases,some maximum and minimum data were deleted to modify the variance.
3. RESULTS
Of 244 AML patients that were studied, 141 (58%) were male and 103 (42%) were female. Of
244 patients that were studied, 49 people had acute myeloid leukemia M1 (20%), 48 had type
M2 (19.6%), 46 had M3 (18.8%), 73 had M4 (29.9%), 20 had M5 (8%), 2 had M6 (0.8%), 3 had
two-phenotype type (1.2 percent).
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165 AML patients were from Fars province that Shiraz, with 60 patients (36%),had the highest
number of the patients referring to hematology-Oncologysection of Namazi hospital. And Shiraz,
cities such as Marvdasht with 16 patients (9.7%), Jahrom with 14 patients (8.5%), Karzerun with
9 patients (5.4%), Fasawith 8 patients (4.8%) and etc. were listed.
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Table 3: The main complaint of AML patients during 94-89 years:















In this study, 141 (58%) of the patients were male and 103 (42%) are female.Unlike survey
conducted by doctor Mahallati, the ratio of men to women was much higher than the reported
statistics. Now, the male to female ratio is 1/36. Like other studies, it is slightly more in men than
in women. With little disturbance,this increase can be achieved in a variety of acute myeloid
leukemia.The prevalence of different types of acute myeloid leukemia is M2 (30-25%), M4 (30-
20%), M1 (20%), M3 (10-5%), M5 (10%), M6 and M7, respectively, each 5% [2].According to
the conducted studies, the most common type was M4 with 73 patients that accounts for 29.9%
of all cases which is statistically meaningfulby P<0.0001.After M4, type M1 with 49 patients
(20%) about P<0.05, M2 with 48 patients (19.6%) stand out.The high prevalence of M3 with 46
cases (18.8%) has a significant increase in comparison with other studieswhich is statistically
significant P<0.0001.The percent of our M6 and M7 patients was much lower compared with
other statistics. The prevalence of both types of leukemia is 5%, and according to our study, M6
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is 0.8 and M7 is(1.2%) and this is not statistically significant because the number of patients in
the two groups is too low. According to our study, the percent of M5 is 8% which does not show
any significant difference with the statistics of other studies. The studied patients aged 14-80
years old.The average age of men with AML ismore than the average age of women who are
suffering AML (37/35 years against 34/3 years)and this ratio is maintained in all types of AML.
It is a matter of controversy that why women in younger age,compared to men, are diagnosed
with AML. M3 patients are younger than other types of AML [7]and this is the case with our
patients. The age of M6 patients is usually higher and their average age is more than 50 years [2-
3]. Likewise in the conducted studies, the mean age of M6patients is higher than with other types
of AML. But because the number of patients was small, it is statistically not significant.Age
distribution of the studied patients was categorized from 14 to 70 and then compared. The
highest percent (22/13) was ascribed to the age group of 29-20 years and then to 39-30 years age
group (21/31%).Unlike other studies in whichits prevalence increases with an increase in age [2,
3, 5 and 8] and half of AML patients areover 60 years of age [5], in our patients, its prevalence
decreases with an increase in age. This is probably due to lower life expectancy and lower
average age of our population in comparison with the studied populations.Detection of new cases
of AML increases from1990 to 1995.So that 9% of patients were diagnosed in1990and 21%of
them were diagnosed in 1994. This increase was maintained in 1995,and this may indicate acute
myeloid leukemia incidence in our population due to industrialization, air pollution or changes in
eating habits and in the people’s lifestyle. Such as increaseduring 1965-75 in the UK had been
reported in studiesand AML incidence had doubled over these years [6].Infection is the
complicationof almost all acute leukemia [5].In most patients there is a fever which is due to
either leukemia or secondary infection [2, 9].The major complaint of our patients was to have a
fever.It accounted for 32% of the major complaint and the reason of theirreferring and in
examining the history, 67% of patients complained of fever or had a febrile history.Weight loss,
which is usually not severe, is seen in 50% of patients [7]. But in this study, only 36% of patients
had a history of weight loss. And the major complaint of only 0.8% of our patients was weight
loss.And this is statistically significant (P <0.0001).Bleeding is a major issue in patients with
acute leukemiaand is mainly related to thrombocytopenia [5]. Thrombocytopenia is almost
always in diagnosis which is due to reduced production and low life-expectancy.Half of the
patients at the time of platelets diagnosis have less than 50 thousand per microliter [3].121 of our
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patients (50%) had signs of bleedingwhile 159 cases (65%) had a platelet count less than 50
thousand per microliter. And this is much higher than other conducted studies P <0.0001 which
is statistically significant.In this study, the relationship between age and the risk of leukemia, sex
and type of leukemia, location and type of leukemia was examined none of which was
statistically significant. Furthermore, the relationship between age and the type of leukemia,
residence location and prognosis was studied that was not statistically significant.
5. CONCLUSION
In our population like the rest of the world, AML disease is more common in men than women,
and this proportion is maintained in all types of AML.Here, the prevalence of acute myeloid
leukemia in order of frequency is M2, M1, M4 and then M5, M3and finally HybridM7 and M6
come which is unlike the statistics of other studies in which M2 is the most common type and
this may be due to the similarity of the two morphologies.The average age of patients with AML
in our population is much lower than similar studies in other countries.AML age distribution of
our population is also against the statistics from other studies.It decreases with an increase in the
age of the patients. And most patients in our study are 29-20 year-olds and then those who are 30
to 39 years old. And this is the antithesis of the available statistics that state this disease is less in
early adulthoodand it is more common with increasing age. A small percentage of our patients
are elderly patientswhich may indicate that our population is young and lower life expectancy in
our population.
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